🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

ReDS-guided Decongestion Strategy in Patients Hospitalized for Heart Failure

RecruitingNAAges 18 Years - anyAllFundacion para la Investigacion Biomedica del Hos…
NCT07484009 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This clinical trial aims to determine whether a ReDS-guided treatment strategy is superior to the current standard of care for adults hospitalized with heart failure. Additionally, the study will evaluate the safety and cost-effectiveness of this approach. The study seeks to answer the following key questions: 1. Does the ReDS-guided strategy reduce the risk of cardiovascular events during the first month following hospital discharge? 2. What is the safety profile of this treatment strategy? Researchers will compare the ReDS-based strategy against the current standard of care. All participants will: * Undergo daily assessments using the ReDS device throughout their hospitalization. * Attend two follow-up visits post-discharge, scheduled at 2 weeks and 30 days.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Hospitalized due to heart failure as the main reason, including the presence of symptoms and signs of congestion, regardless of the left ventricular ejection fraction (LVEF). 2. NT-proBNP greater than 1000 pg/L or BNP greater than 300 pg/L upon admission. Exclusion Criteria: 1. Height less than 150 cm or greater than 190 cm or body mass index (BMI) less than 22 or greater than 39, conditions where the use of ReDS is not approved. 2. Patients requiring inotropes (levosimendan is allowed) or vasopressors upon admission, with mechanical support, or heart transplant recipients. 3. Any malformation or variant affecting the right lung anatomy (e.g., a pacemaker). 4. Patients with any heart disease requiring a planned surgical intervention (CABG, valve disease, or other) or percutaneous (TAVR, STE-ACS, mitral or tricuspid valve repair, CRT) during the clinical trial. 5. Chronic kidney disease with a GFR \<20 or on hemodialysis. 6. Life expectancy less than 12 months due to non-cardiological origin. 7. Participation in another clinical trial with intervention.
💊

What it tests

  • Remote Dielectric Sensing System
  • Blinded ReDS data
📍

Where

25 sites
Ramón y Cajal University Hospital
Madrid, Spain
Arnau de Vilanova University Hospital
Barcelona, Spain
Bellvitge University Hospital
Barcelona, Spain
Hospital Clinic
Barcelona, Spain
Hospital del Mar
Barcelona, Spain
Vall d'Hebrón University Hospital
Barcelona, Spain
Reina Sofía University Hospital
Córdoba, Spain
Dr Josep Trueta University Hospital
Girona, Spain

…and 17 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy